Payment overview · 2025
General Payments
$314,703.51
271 reported records · 22 companies
Healthcare provider profile · identity verified
Lance L Stein, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Transplant Hepatology · ATLANTA, GA · NPI 1568558062
Verified facts
What the public records show
CMS Open Payments records show Lance L Stein, MD received $314,703.51 in general payments during 2025 across 271 reported records.
Madrigal Pharmaceuticals accounted for 43.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ocaliva, Rezdiffra, Xifaxan.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vemlidy by this doctor in 2024.
Intercept Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OCALIVA as an associated drug or biological on 9842 records involving 5240 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ocaliva by this doctor in 2024.
Madrigal Pharmaceuticals reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REZDIFFRA as an associated drug or biological on 75650 records involving 19195 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rezdiffra by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $136,877.73 | 43.5% | 87 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $75,188.08 | 23.9% | 45 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $60,492.73 | 19.2% | 32 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $22,204.63 | 7.1% | 38 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14,684.91 | 4.7% | 13 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $2,187.50 | 0.7% | 1 | 2025 |
| Intercept Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $1,467.15 | 0.5% | 13 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $729.07 | 0.2% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $254.01 | 0.1% | 6 | 2025 |
| Fujifilm Healthcare Americas Corporation | Unresolved — no canonical attribution shown | $125.00 | 0.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $83.09 | 0.0% | 3 | 2025 |
| ORPHALAN INC | Unresolved — no canonical attribution shown | $76.31 | 0.0% | 4 | 2025 |
| TriSalus Life Sciences, Inc. | Unresolved — no canonical attribution shown | $51.63 | 0.0% | 2 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $47.50 | 0.0% | 2 | 2025 |
| Sirtex Medical Inc | Unresolved — no canonical attribution shown | $46.15 | 0.0% | 2 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $42.58 | 0.0% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.44 | 0.0% | 2 | 2025 |
| Mirum Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.71 | 0.0% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.52 | 0.0% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.85 | 0.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.80 | 0.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.12 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $281,600.00 | 66 |
| Consulting Fee | $17,323.50 | 7 |
| Travel and Lodging | $8,934.29 | 54 |
| Food and Beverage | $6,845.72 | 144 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $136,877.73 | 87 | 2025 |
Source payment records
|
|||||
| TERLIVAZ Normalized: terlivaz |
Drug | Mallinckrodt Hospital Products Inc. | $60,492.73 | 32 | 2025 |
Source payment records
|
|||||
| IQIRVO Normalized: iqirvo |
Drug | Ipsen Biopharmaceuticals, Inc | $54,912.42 | 34 | 2025 |
Source payment records
|
|||||
| Livdelzi Normalized: livdelzi |
Drug | Gilead Sciences, Inc. | $21,133.89 | 24 | 2025 |
Source payment records
|
|||||
| Bylvay Normalized: bylvay |
Drug | Ipsen Biopharmaceuticals, Inc | $20,275.66 | 11 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $14,684.91 | 13 | 2025 |
Source payment records
|
|||||
| OCALIVA Normalized: ocaliva |
Drug | Intercept Pharmaceuticals, Inc. | $1,467.15 | 13 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $729.07 | 14 | 2025 |
Source payment records
|
|||||
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $670.20 | 3 | 2025 |
Source payment records
|
|||||
| PLENVU Normalized: plenvu |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $208.06 | 12 | 2025 |
Source payment records
|
|||||
| UTASWAKO AFP-L3 Normalized: utaswako afp l3 |
Device | Fujifilm Healthcare Americas Corporation | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| CUVRIOR Normalized: cuvrior |
Drug | ORPHALAN INC | $76.31 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $71.43 | 4 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $55.15 | 2 | 2025 |
Source payment records
|
|||||
| TRINAV INFUSION SYSTEM Normalized: trinav infusion system |
Device | TriSalus Life Sciences, Inc. | $51.63 | 2 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $47.50 | 2 | 2025 |
Source payment records
|
|||||
| SIR-Spheres Microspheres Normalized: sir spheres microspheres |
Device | Sirtex Medical Inc | $46.15 | 2 | 2025 |
Source payment records
|
|||||
| SURGICEL NU-KNIT Normalized: surgicel nu knit |
Device | Ethicon US, LLC | $42.58 | 1 | 2025 |
Source payment records
|
|||||
| VISTASEAL Normalized: vistaseal |
Biological | Ethicon US, LLC | $42.58 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $36.44 | 2 | 2025 |
Source payment records
|
|||||
| Livmarli Normalized: livmarli |
Drug | Mirum Pharmaceuticals, Inc. | $24.71 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| Cresemba Normalized: cresemba |
Drug | Astellas Pharma US Inc | $17.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| OCALIVA ocaliva |
2025 | Ocaliva | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REZDIFFRA rezdiffra |
2025 | Rezdiffra | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 139 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Intercept Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OCALIVA open payments reported associated product |
CMS Open Payments — General Payments 9842 supporting records · 5240 recipient NPIs · example record 1249867901 |
Ocaliva · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Madrigal Pharmaceuticals Exact reporting entity; no affiliate inference |
2025 | REZDIFFRA open payments reported associated product |
CMS Open Payments — General Payments 75650 supporting records · 19195 recipient NPIs · example record 1248227746 |
Rezdiffra · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
139 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Xifaxan | Rifaximin | 139 | 23 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 132 | 30 |
| Tacrolimus | Tacrolimus | 115 | 31 |
| Lactulose | Lactulose | 106 | 30 |
| Ursodiol | Ursodiol | 101 | 22 |
| Azathioprine | Azathioprine | 93 | 24 |
| Spironolactone | Spironolactone | 87 | 36 |
| Prednisone | Prednisone | 66 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 62 | 22 |
| Furosemide | Furosemide | 58 | 28 |
| Carvedilol | Carvedilol | 46 | 15 |
| Ocaliva | Obeticholic Acid | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 25 | suppressed |
| Sirolimus | Sirolimus | 24 | suppressed |
| Omeprazole | Omeprazole | 19 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 18 | suppressed |
| Valganciclovir Hcl | Valganciclovir Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Rezdiffra | Resmetirom | 17 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 17 | suppressed |
| Cyclosporine Modified | Cyclosporine, Modified | 16 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Everolimus | Everolimus | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Entecavir | Entecavir | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $314,703.51 · 271 records | Madrigal Pharmaceuticals | Bylvay, CUVRIOR, Cresemba, Epclusa, IQIRVO, Livdelzi, Livmarli, MAVYRET, OCALIVA, PEMGARDA, PLENVU, PURIFIED CORTROPHIN GEL, REZDIFFRA, SIR-Spheres Microspheres, SURGICEL NU-KNIT, TERLIVAZ, TRINAV INFUSION SYSTEM, ULTOMIRIS, UPLIZNA, UTASWAKO AFP-L3, VISTASEAL, Wegovy, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ocaliva play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error